CN106661039B - 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途 - Google Patents

酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途 Download PDF

Info

Publication number
CN106661039B
CN106661039B CN201580021113.2A CN201580021113A CN106661039B CN 106661039 B CN106661039 B CN 106661039B CN 201580021113 A CN201580021113 A CN 201580021113A CN 106661039 B CN106661039 B CN 106661039B
Authority
CN
China
Prior art keywords
compound
nitrogen
sulfur
disorder
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580021113.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN106661039A (zh
Inventor
卡格·E·玛斯
杰诺米·罗伯特·葛林伍德
多娜·L·罗曼罗
吉瑞狄恩·C·哈瑞玛
罗讷德·T·威斯特
蜜·莎丽
乔舒亚·杰米尔·肯尼迪-史密斯
马库斯·道葛林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Lin Xu M Lakshmi Hakushi Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lin Xu M Lakshmi Hakushi Co filed Critical Lin Xu M Lakshmi Hakushi Co
Publication of CN106661039A publication Critical patent/CN106661039A/zh
Application granted granted Critical
Publication of CN106661039B publication Critical patent/CN106661039B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580021113.2A 2014-02-28 2015-02-27 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途 Active CN106661039B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461946358P 2014-02-28 2014-02-28
US61/946,358 2014-02-28
US201461971376P 2014-03-27 2014-03-27
US61/971,376 2014-03-27
US201462096231P 2014-12-23 2014-12-23
US62/096,231 2014-12-23
PCT/US2015/018071 WO2015131080A1 (en) 2014-02-28 2015-02-27 Tyk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CN106661039A CN106661039A (zh) 2017-05-10
CN106661039B true CN106661039B (zh) 2019-09-13

Family

ID=54009662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580021113.2A Active CN106661039B (zh) 2014-02-28 2015-02-27 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途

Country Status (9)

Country Link
US (3) US9340540B2 (https=)
EP (2) EP3110820B1 (https=)
JP (2) JP6526065B2 (https=)
CN (1) CN106661039B (https=)
AU (1) AU2015222865B2 (https=)
CA (1) CA2940666C (https=)
ES (1) ES2921874T3 (https=)
TW (2) TWI701245B (https=)
WO (1) WO2015131080A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788655B (zh) * 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
TWI707852B (zh) 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
TW202515876A (zh) * 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
US11419883B2 (en) 2017-05-05 2022-08-23 The Regents Of The University Of California Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
SI3658557T1 (sl) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
AU2018312349A1 (en) * 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
US11174254B2 (en) * 2017-09-28 2021-11-16 Yangtze River Pharmaceutical Group Co., Ltd. Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CN111194319A (zh) * 2017-10-19 2020-05-22 拜耳动物保健有限责任公司 稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途
CN111386272B (zh) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US12486320B1 (en) * 2018-01-15 2025-12-02 Washington University Compositions and methods for treatment of central nervous system (CNS) autoimmune associated diseases or disorders
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
EP3768272B1 (en) * 2018-03-21 2025-07-30 Xibin Liao Jak inhibitors
CN108409638A (zh) * 2018-05-18 2018-08-17 东南大学 一种Niraparib中间体（S）-3-（4-溴苯基）哌啶的制备方法
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN113348021B (zh) 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途
US20220025510A1 (en) 2019-03-15 2022-01-27 Mitsubishi Materials Corporation Tungsten oxide sputtering target
US20210395247A1 (en) * 2019-03-18 2021-12-23 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Btk inhibitors, pharmaceutically acceptable salts, polymorphs and application thereof
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
MX2022002877A (es) 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
US20230089247A1 (en) * 2019-12-24 2023-03-23 Zydus Lifesciences Limited Novel compounds suitable for the treatment of dyslipidemia
CN119684299A (zh) * 2020-03-13 2025-03-25 阿斯利康(瑞典)有限公司 作为kcc2调节剂的稠合的嘧啶化合物
CN111269134B (zh) * 2020-04-01 2022-09-20 九江中星医药化工有限公司 一种苯甘氨酸及其衍生物的制备方法
CA3191607A1 (en) 2020-09-08 2022-03-17 Gilles Ouvry Novel jak inhibitor compounds, method for synthesizing same and use thereof
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
CN114644566A (zh) * 2020-12-21 2022-06-21 抚顺顺能化工有限公司 一种2-氨基-2-苯基丁酸的制备方法
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
MX2023009060A (es) 2021-02-02 2023-09-29 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
EP4291235A4 (en) 2021-02-12 2025-01-08 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
WO2022179578A1 (zh) * 2021-02-24 2022-09-01 南京明德新药研发有限公司 含有亚磺酰基吡啶结构的化合物以及应用
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US12325697B2 (en) 2021-04-09 2025-06-10 Nimbus Clio, Inc. CBL-B modulators and uses thereof
JP7740849B2 (ja) * 2021-05-04 2025-09-17 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド 含窒素複素環ピリジン化合物
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CA3241096A1 (en) * 2021-12-02 2023-06-08 Beigene Switzerland Gmbh Methods of synthesis of chiral 3,5-disubstituted morpholine compounds a nd intermediates useful therein
IL318577A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
US20260028330A1 (en) 2022-08-02 2026-01-29 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
KR20250056924A (ko) 2022-08-02 2025-04-28 리미널 바이오사이언시스 리미티드 치환된 피리돈 gpr84 길항제 및 이의 용도
AU2024344754A1 (en) 2023-09-21 2026-04-02 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
WO2025188952A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
WO2025188974A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics
US20260048062A1 (en) * 2024-03-06 2026-02-19 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
WO2009062258A1 (en) * 2007-11-15 2009-05-22 Cytopia Research Pty Ltd N-containing heterocyclic compounds
CN101626767A (zh) * 2005-05-18 2010-01-13 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
CN102633716A (zh) * 2003-11-19 2012-08-15 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
CN102753548A (zh) * 2009-12-23 2012-10-24 武田药品工业株式会社 作为syk抑制剂的稠合的杂芳族吡咯烷酮
WO2012178125A1 (en) * 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN102869359A (zh) * 2010-03-17 2013-01-09 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶和嘌呤化合物、组合物和使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
KR20080011199A (ko) * 2005-04-19 2008-01-31 교와 핫꼬 고교 가부시끼가이샤 질소 함유 복소환 화합물
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2211620B1 (en) * 2007-10-25 2013-12-25 Merck Sharp & Dohme Corp. 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
CN102633716A (zh) * 2003-11-19 2012-08-15 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
CN101626767A (zh) * 2005-05-18 2010-01-13 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
WO2009062258A1 (en) * 2007-11-15 2009-05-22 Cytopia Research Pty Ltd N-containing heterocyclic compounds
CN102753548A (zh) * 2009-12-23 2012-10-24 武田药品工业株式会社 作为syk抑制剂的稠合的杂芳族吡咯烷酮
CN102869359A (zh) * 2010-03-17 2013-01-09 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶和嘌呤化合物、组合物和使用方法
WO2012178125A1 (en) * 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase

Also Published As

Publication number Publication date
CA2940666C (en) 2022-08-23
EP3110820B1 (en) 2022-04-06
JP2019048885A (ja) 2019-03-28
WO2015131080A1 (en) 2015-09-03
JP2017506675A (ja) 2017-03-09
US10196390B2 (en) 2019-02-05
AU2015222865B2 (en) 2019-06-20
TW201936606A (zh) 2019-09-16
TWI754794B (zh) 2022-02-11
US20150266875A1 (en) 2015-09-24
US9340540B2 (en) 2016-05-17
JP6526065B2 (ja) 2019-06-05
EP3110820A4 (en) 2017-10-04
EP4019518A1 (en) 2022-06-29
TW201620907A (zh) 2016-06-16
CA2940666A1 (en) 2015-09-03
US9630970B2 (en) 2017-04-25
ES2921874T3 (es) 2022-09-01
TWI701245B (zh) 2020-08-11
AU2015222865A1 (en) 2016-09-08
US20170247373A1 (en) 2017-08-31
EP3110820A1 (en) 2017-01-04
CN106661039A (zh) 2017-05-10
US20160297826A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
CN106661039B (zh) 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
AU2023237060B2 (en) TYK2 inhibitors and uses thereof
EP3344624B1 (en) Tyk2 inhibitors and uses thereof
HK40075858A (en) Tyk2 inhibitors and uses thereof
HK1232534A1 (en) Tyk2 inhibitors and uses thereof
HK1232534B (en) Tyk2 inhibitors and uses thereof
HK40055822A (en) Tyk2 inhibitors and uses thereof
HK40055822B (en) Tyk2 inhibitors and uses thereof
BR112016019881B1 (pt) Compostos inibidores de tyk2, composição farmacêutica compreendendo os referidos compostos, usos dos mesmos e método de inibir tyk2 em uma amostra biológica
HK40009936A (en) Tyk2 inhibitors and uses thereof
HK40009936B (en) Tyk2 inhibitors and uses thereof
HK1256997B (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231127

Address after: Osaka, Japan

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts

Patentee before: NIMBUS LAKSHMI, Inc.